← Leaderboards
Mike Glode
Aurora Oncology, Inc.
$1,299,359
Attributed
$2,449,677
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2012–23$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,449,677 · 2
By mechanism
R44$2,300,637 · 1
R43$149,040 · 1
Top collaborators
- Shawn Patrick Zinnen3 shared
Most similar at Aurora Oncology, Inc.
Same institution · by research overlap
- Shawn Patrick Zinnen$4,227,093
Others in their field
Top investigators on “Malignant Neoplasm Of Urinary Bladder”
- David Heimbrook · Leidos Biomedical Research, Inc.$89,819,252
- Walter John Curran · Thomas Jefferson University$36,890,150
- Norman Wolmark · Nsabp Foundation, Inc.$33,598,810
- Robert S Mannel · University Of Oklahoma Hlth Sciences Ctr$33,598,810
- Quynh-Thu X Le · Stanford University$23,198,964
- Larry Arthur$21,899,494
Research focus
Malignant Neoplasm Of Urinary BladderSafetyExcisionIn VivoProteinsRecurrenceDiphtheria ToxinEpidermal Growth Factor ReceptorApplications GrantsFusion ToxinNovel StrategiesNude MiceCancer CellCystectomyAggressive TherapyDesignEpidermal Growth FactorCell KillingCellsCessation Of LifeChimeric ProteinsBladderMalignant NeoplasmsSmall Business Innovation Research Grant
Grant awards (4)
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer$999,955
R44 · FY2023 · CA · contact PI
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer$1,000,745
R44 · FY2020 · CA · contact PI
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer$299,937
R44 · FY2018 · CA · contact PI
DT-EGF Toxic Fusion Protein for Treatment of Bladder Cancer$149,040
R43 · FY2012 · CA · contact PI